Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS Negl Trop Dis ; 15(11): e0009951, 2021 11.
Article in English | MEDLINE | ID: mdl-34780470

ABSTRACT

With current drug treatments failing due to toxicity, low efficacy and resistance; leishmaniasis is a major global health challenge that desperately needs new validated drug targets. Inspired by activity of the natural chalcone 2',6'-dihydroxy-4'-methoxychalcone (DMC), the nitro-analogue, 3-nitro-2',4',6'- trimethoxychalcone (NAT22, 1c) was identified as potent broad spectrum antileishmanial drug lead. Structural modification provided an alkyne containing chemical probe that labelled a protein within the parasite that was confirmed as cytosolic tryparedoxin peroxidase (cTXNPx). Crucially, labelling is observed in both promastigote and intramacrophage amastigote life forms, with no evidence of host macrophage toxicity. Incubation of the chalcone in the parasite leads to ROS accumulation and parasite death. Deletion of cTXNPx, by CRISPR-Cas9, dramatically impacts upon the parasite phenotype and reduces the antileishmanial activity of the chalcone analogue. Molecular docking studies with a homology model of in-silico cTXNPx suggest that the chalcone is able to bind in the putative active site hindering access to the crucial cysteine residue. Collectively, this work identifies cTXNPx as an important target for antileishmanial chalcones.


Subject(s)
Antiprotozoal Agents/therapeutic use , Chalcone/metabolism , Chalcone/pharmacology , Cytosol/drug effects , Leishmania/drug effects , Peroxidases/antagonists & inhibitors , Protozoan Proteins/antagonists & inhibitors , Animals , Antiprotozoal Agents/administration & dosage , Antiprotozoal Agents/pharmacology , Cells, Cultured , Chalcone/administration & dosage , Chalcone/analogs & derivatives , Cytosol/enzymology , Cytosol/parasitology , Drug Discovery , Humans , Leishmania/classification , Leishmaniasis/drug therapy , Leishmaniasis/parasitology , Macrophages/drug effects , Macrophages/parasitology , Mice , Mice, Inbred BALB C , Molecular Docking Simulation , Peroxidases/metabolism , Protozoan Proteins/metabolism
2.
ACS Infect Dis ; 7(1): 47-63, 2021 01 08.
Article in English | MEDLINE | ID: mdl-33291887

ABSTRACT

Current chemotherapeutics for leishmaniasis have multiple deficiencies, and there is a need for new safe, efficacious, and affordable medicines. This study describes a successful drug repurposing approach that identifies the over-the-counter antihistamine, clemastine fumarate, as a potential antileishmanial drug candidate. The screening for inhibitors of the sphingolipid synthase (inositol phosphorylceramide synthase, IPCS) afforded, following secondary screening against Leishmania major (Lmj) promastigotes, 16 active compounds. Further refinement through the dose response against LmjIPCS and intramacrophage L. major amastigotes identified clemastine fumarate with good activity and selectivity with respect to the host macrophage. On target engagement was supported by diminished sensitivity in a sphingolipid-deficient L. major mutant (ΔLmjLCB2) and altered phospholipid and sphingolipid profiles upon treatment with clemastine fumarate. The drug also induced an enhanced host cell response to infection indicative of polypharmacology. The activity was sustained across a panel of Old and New World Leishmania species, displaying an in vivo activity equivalent to the currently used drug, glucantime, in a mouse model of L. amazonensis infection. Overall, these data validate IPCS as an antileishmanial drug target and indicate that clemastine fumarate is a candidate for repurposing for the treatment of leishmaniasis.


Subject(s)
Antiprotozoal Agents , Leishmaniasis , Pharmaceutical Preparations , Animals , Antiprotozoal Agents/pharmacology , Clemastine/therapeutic use , Inositol , Leishmaniasis/drug therapy , Mice
3.
Parasitology ; 145(2): 219-236, 2018 02.
Article in English | MEDLINE | ID: mdl-28805165

ABSTRACT

Leishmaniasis is a vector-borne neglected tropical disease caused by protozoan parasites of the genus Leishmania for which there is a paucity of effective viable non-toxic drugs. There are 1·3 million new cases each year causing considerable socio-economic hardship, best measured in 2·4 million disability adjusted life years, with greatest impact on the poorest communities, which means that desperately needed new antileishmanial treatments have to be both affordable and accessible. Established medicines with cheaper and faster development times may hold the cure for this neglected tropical disease. This concept of using old drugs for new diseases may not be novel but, with the ambitious target of controlling or eradicating tropical diseases by 2020, this strategy is still an important one. In this review, we will explore the current state-of-the-art of drug repurposing strategies in the search for new treatments for leishmaniasis.


Subject(s)
Antiprotozoal Agents/pharmacology , Drug Discovery/methods , Drug Repositioning/methods , Animals , Antiprotozoal Agents/therapeutic use , Drug Discovery/trends , Humans , Leishmania/drug effects , Leishmaniasis/drug therapy , Neglected Diseases/drug therapy , Neglected Diseases/parasitology
SELECTION OF CITATIONS
SEARCH DETAIL
...